Increased adverse events associated with antiepileptic drugs in anti–leucine‐rich glioma‐inactivated protein 1 encephalitis

• DOI: 10.1111/epi.14490
• Publication Date: 2018-08-30T10:45:55Z
• Authors: Yong‐Won Shin; Seon‐Jae Ahn; Jangsup Moon; Tae‐Joon Kim; Jin‐Sun Jun; Jung‐Ick Byun; Soon‐Tae Lee; Keun‐Hwa Jung; Kyung‐Il Park; Ki‐Young Jung; Manho Kim; Sang Kun Lee; Kon Chu
• Keywords: Levetiracetam; Autoimmune encephalitis; Oxcarbazepine; Maculopapular rash; Irritability

Summary Anti–leucine‐rich glioma‐inactivated protein 1 ( LGI 1) encephalitis is a rare autoimmune condition presenting mainly as altered mental state, cognitive dysfunction, and seizure. Antiepileptic drugs AED s) are usually initiated to control seizures despite their limited efficacy; however, accumulating clinical experience suggests high incidence of adverse reactions s in anti‐ encephalitis. We reviewed the medical records patients who were diagnosed with analyze effects these patients. Among 20 treated s, 10 (50%) changed due cutaneous drug reaction. Eight them presented maculopapular eruption, one rash eosinophilia systemic symptoms syndrome, eczema. Causative agents mostly consisted aromatic s. Oxcarbazepine was discontinued two additional hyponatremia. Six (30%) dose levetiracetam because psychiatric manifestations including irritability/aggressive behavior (four patients), insomnia (one patient), depressive mood patient). Clinicians should consider reaction, events, hyponatremia when selecting for treatment